From July the EC will require that gelatin used in parenteral drugs is sourced from countries in World Organisation for Animal Health's (OIE) lowest risk categories for bovine spongiform encephalopathy (BSE).
US raw materials supplier Originates has boosted its pharmaceutical bovine hide gelatin manufacturing capacity with the addition of two new ISO 9000/9001 certified, GMP-standard production facilities in South America.
Operations at SAFC Biosciences’ facility in Kansas, US have been made animal component-free (ACF) under a division-wide strategy to keep pace with customer demands and changing regulations.
Bio-Rad Laboratories has reported strong growth in the last quarter
of 2007, with a 34 per cent increase in revenue compared to the
last quarter of 2006. These results have contributed to an overall
14.7 per cent increase in sales...
A new recombinant pig liver esterase (PLE) biocatalyst that
sidesteps concerns about the safety of animal-derived versions has
been launched by DSM Pharma Chemicals.
Japan's Chugai Pharmaceuticals is voluntarily recalling almost 2000
bottles of Vesanoid capsules (tretinoin) after the drug was found
to contain unapproved bovine-derived material from Canada.
Canada's National Centre for Foreign Animal Disease (NCFAD) has
been designated as a reference lab for Bovine Spongiform
Encephalopathy (BSE) by the World Organisation for Animal Health
known as the OIE.
Invitrogen has opened a bioproduction facility in Australia to make
bovine sera products and reagents used in basic research and the
production of vaccines and biotherapeutic drugs.
Celliance has introduced a new bovine albumin product, manufactured
exclusively from animals originating in Australia, that is aimed at
applications such as pharmaceuticals where there is a need to
ensure the absence of transmissible...
Recently-formed cell culture specialist Celliance has introduced a
new supplement designed to boost the growth of cells used in
research and bioprocessing, that does not contain fetal bovine
serum.
Pall is gearing up to launch a new filter technology in Europe that
can remove prions - the infectious agents that cause mad cow
disease and its human form Creutzfeldt-Jakob disease (vCJD) - from
blood and blood products.
The emergence of cases of mad cow disease in North America has not
raised any public health concern from animal-derived medicinal
materials such as bovine blood derivatives and gelatin.
US company STERIS has achieved a significant breakthrough in
aseptic processing with the development of a method for
inactivating prions, the tiny, protein particles that cause
diseases such as CJD disease in humans.
Fisher Scientific subsidiary Perbio last week opened a new facility
in the UK to manufacture its Hyclone range of cell culture
equipment and mediathat ramps up its liquid production capacity by
a factor of four, reports Phil Taylor.
Sigma-Aldrich's fine chemicals unit is to distribute a
plant-produced recombinant aprotinin manufactured by US-based Large
Scale Biology Corporation, under a new agreement announced this
week.
The US market for media, sera and reagents used in cell culture is
expected to nearly double in value to reach $1.7 billion (€1.48bn)
in 2008, according to a report.
The market for cell culture products is getting a lift from
stringent regulations from the US FDA and Department of
Agriculture, restricting the importation and usage of foetal bovine
serum